Literature DB >> 23348886

Is a strategy based on routine endotracheal cultures the best way to prescribe antibiotics in ventilator-associated pneumonia?

Carlos M Luna1, Sergio Sarquis2, Michael S Niederman3, Fernando A Sosa2, Maria Otaola2, Nicolas Bailleau2, Carlos A Vay4, Angela Famiglietti4, Célica Irrazabal2, Abelardo A Capdevila2.   

Abstract

OBJECTIVES: The objectives of this study were to evaluate if a strategy based on routine endotracheal aspirate (ETA) cultures is better than using the American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines to prescribe antimicrobials in ventilator-associated pneumonia (VAP).
METHODS: This was a prospective, observational, cohort study conducted in a 15-bed ICU and comprising 283 patients who were mechanically ventilated for ≥48 h. Interventions included twice-weekly ETA; BAL culture was done if VAP was suspected. BAL (collected at the time of VAP) plus ETA cultures (collected≤7 days before VAP) (n=146 different pairs) were defined. We compared two models of 10 days of empirical antimicrobials (ETA-based vs ATS/IDSA guidelines-based strategies), analyzing their impact on appropriateness of therapy and total antimicrobial-days, using the BAL result as the standard for comparison.
RESULTS: Complete ETA and BAL culture concordance (identical pathogens or negative result) occurred in 52 pairs; discordance (false positive or false negative) in 67, and partial concordance in two. ETA predicted the etiology in 62.4% of all pairs, in 74.0% of pairs if ETA was performed≤2 days before BAL, and in 46.2% of pairs if ETA was performed 3 to 7 days before BAL (P=.016). Strategies based on the ATS/IDSA guidelines and on ETA results led to appropriate therapy in 97.9% and 77.4% of pairs, respectively (P<.001). The numbers of antimicrobial-days were 1,942 and 1,557 for therapies based on ATS/IDSA guidelines and ETA results, respectively (P<.001).
CONCLUSIONS: The ATS/IDSA guidelines-based approach was more accurate than the ETA-based strategy for prescribing appropriate, initial, empirical antibiotics in VAP, unless a sample was available≤2 days of the onset of VAP. The ETA-based strategy led to fewer days on prescribed antimicrobials.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23348886     DOI: 10.1378/chest.12-1477

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  18 in total

1.  Endotracheal aspirate and bronchoalveolar lavage fluid analysis: interchangeable diagnostic modalities in suspected ventilator-associated pneumonia?

Authors:  Johannes B J Scholte; Helke A van Dessel; Catharina F M Linssen; Dennis C J J Bergmans; Paul H M Savelkoul; Paul M H J Roekaerts; Walther N K A van Mook
Journal:  J Clin Microbiol       Date:  2014-07-30       Impact factor: 5.948

2.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

Review 3.  Airway microbiome research: a modern perspective on surveillance cultures?

Authors:  Damien Roux; Pouline M van Oort; Jean-Damien Ricard; Lieuwe D J Bos
Journal:  Ann Transl Med       Date:  2017-11

4.  Imipenem/Cilastatin/Relebactam Alone and in Combination against Pseudomonas aeruginosa in the In Vitro Pharmacodynamic Model.

Authors:  Iris H Chen; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

5.  Systematic review of studies investigating ventilator associated pneumonia diagnostics in intensive care.

Authors:  Basem Al-Omari; Peter McMeekin; A Joy Allen; Ahsan R Akram; Sara Graziadio; Jana Suklan; William S Jones; B Clare Lendrem; Amanda Winter; Milo Cullinan; Joanne Gray; Kevin Dhaliwal; Timothy S Walsh; Thomas H Craven
Journal:  BMC Pulm Med       Date:  2021-06-09       Impact factor: 3.317

Review 6.  Year in review 2013: Critical Care--respiratory infections.

Authors:  Girish B Nair; Michael S Niederman
Journal:  Crit Care       Date:  2014-10-29       Impact factor: 9.097

7.  How to approach and treat VAP in ICU patients.

Authors:  Bárbara Borgatta; Jordi Rello
Journal:  BMC Infect Dis       Date:  2014-04-30       Impact factor: 3.090

8.  Impact of appropriate antimicrobial treatment on transition from ventilator-associated tracheobronchitis to ventilator-associated pneumonia.

Authors:  Saad Nseir; Ignacio Martin-Loeches; Demosthenes Makris; Emmanuelle Jaillette; Marios Karvouniaris; Jordi Valles; Epaminondas Zakynthinos; Antonio Artigas
Journal:  Crit Care       Date:  2014-06-23       Impact factor: 9.097

Review 9.  Gram-negative infections in adult intensive care units of latin america and the Caribbean.

Authors:  Carlos M Luna; Eduardo Rodriguez-Noriega; Luis Bavestrello; Manuel Guzmán-Blanco
Journal:  Crit Care Res Pract       Date:  2014-11-27

10.  Development of antibiotic treatment algorithms based on local ecology and respiratory surveillance cultures to restrict the use of broad-spectrum antimicrobial drugs in the treatment of hospital-acquired pneumonia in the intensive care unit: a retrospective analysis.

Authors:  Liesbet De Bus; Lies Saerens; Bram Gadeyne; Jerina Boelens; Geert Claeys; Jan J De Waele; Dominique D Benoit; Johan Decruyenaere; Pieter O Depuydt
Journal:  Crit Care       Date:  2014-07-15       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.